TY - JOUR
T1 - Targeting Human Central Nervous System Protein Kinases
T2 - An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models
AU - Roy, Saktimayee M.
AU - Grum-Tokars, Valerie L.
AU - Schavocky, James P.
AU - Saeed, Faisal
AU - Staniszewski, Agnieszka
AU - Teich, Andrew F.
AU - Arancio, Ottavio
AU - Bachstetter, Adam D.
AU - Webster, Scott J.
AU - Van Eldik, Linda J.
AU - Minasov, George
AU - Anderson, Wayne F.
AU - Pelletier, Jeffrey C.
AU - Watterson, D. Martin
N1 - Publisher Copyright:
© 2015 American Chemical Society.
PY - 2015/4/15
Y1 - 2015/4/15
N2 - The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncology indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications. Stress kinases are of special interest in neurological and neuropsychiatric disorders due to their involvement in synaptic dysfunction and complex disease susceptibility. Clinical and preclinical evidence implicates the stress related kinase p38αMAPK as a potential neurotherapeutic target, but isoform selective p38αMAPK inhibitor candidates are lacking and the mixed kinase inhibitor drugs that are promising in peripheral tissue disease indications have limitations for neurologic indications. Therefore, pursuit of the neurotherapeutic hypothesis requires kinase isoform selective inhibitors with appropriate neuropharmacology features. Synaptic dysfunction disorders offer a potential for enhanced pharmacological efficacy due to stress-induced activation of p38αMAPK in both neurons and glia, the interacting cellular components of the synaptic pathophysiological axis, to be modulated. We report a novel isoform selective p38αMAPK inhibitor, MW01-18-150SRM (=MW150), that is efficacious in suppression of hippocampal-dependent associative and spatial memory deficits in two distinct synaptic dysfunction mouse models. A synthetic scheme for biocompatible product and positive outcomes from pharmacological screens are presented. The high-resolution crystallographic structure of the p38αMAPK/MW150 complex documents active site binding, reveals a potential low energy conformation of the bound inhibitor, and suggests a structural explanation for MW150's exquisite target selectivity. As far as we are aware, MW150 is without precedent as an isoform selective p38MAPK inhibitor or as a kinase inhibitor capable of modulating in vivo stress related behavior. (Graph Presented).
AB - The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncology indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications. Stress kinases are of special interest in neurological and neuropsychiatric disorders due to their involvement in synaptic dysfunction and complex disease susceptibility. Clinical and preclinical evidence implicates the stress related kinase p38αMAPK as a potential neurotherapeutic target, but isoform selective p38αMAPK inhibitor candidates are lacking and the mixed kinase inhibitor drugs that are promising in peripheral tissue disease indications have limitations for neurologic indications. Therefore, pursuit of the neurotherapeutic hypothesis requires kinase isoform selective inhibitors with appropriate neuropharmacology features. Synaptic dysfunction disorders offer a potential for enhanced pharmacological efficacy due to stress-induced activation of p38αMAPK in both neurons and glia, the interacting cellular components of the synaptic pathophysiological axis, to be modulated. We report a novel isoform selective p38αMAPK inhibitor, MW01-18-150SRM (=MW150), that is efficacious in suppression of hippocampal-dependent associative and spatial memory deficits in two distinct synaptic dysfunction mouse models. A synthetic scheme for biocompatible product and positive outcomes from pharmacological screens are presented. The high-resolution crystallographic structure of the p38αMAPK/MW150 complex documents active site binding, reveals a potential low energy conformation of the bound inhibitor, and suggests a structural explanation for MW150's exquisite target selectivity. As far as we are aware, MW150 is without precedent as an isoform selective p38MAPK inhibitor or as a kinase inhibitor capable of modulating in vivo stress related behavior. (Graph Presented).
KW - Signal transduction
KW - chemical synthesis
KW - cognitive dysfunction
KW - crystallography
KW - pharmacology
KW - protein kinase
UR - http://www.scopus.com/inward/record.url?scp=84927920792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927920792&partnerID=8YFLogxK
U2 - 10.1021/acschemneuro.5b00002
DO - 10.1021/acschemneuro.5b00002
M3 - Article
C2 - 25676389
AN - SCOPUS:84927920792
VL - 6
SP - 666
EP - 680
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 4
ER -